Biologically Active Small Molecules

A cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.

A cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.

A cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.

A cyclic nitrone spin trap that can be used for the detection and characterization of thiyl radicals, hydroxyl radicals, and superoxide anions in vitro or in vivo.

A neutral RAR&alpha-selective antagonist (Ki = 2.5 nM) antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.

A neutral RAR&alpha-selective antagonist (Ki = 2.5 nM) antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.

A neutral RAR&alpha-selective antagonist (Ki = 2.5 nM) antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.

A cell-permeable ACL inhibitor (IC₅₀ = 0.13 &microM) that has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.

A cell-permeable ACL inhibitor (IC₅₀ = 0.13 &microM) that has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.

A cell-permeable ACL inhibitor (IC₅₀ = 0.13 &microM) that has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.

A cell-permeable ACL inhibitor (IC₅₀ = 0.13 &microM) that has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.

A selective, cell permeable inhibitor of the I&kappaB kinases IKK&alpha and IKK&beta (IC₅₀s = 4 and 0.3 &microM) inhibits signaling through NF-&kappaB both in cells and in vivo, showing excellent pharmacokinetics in mice.